Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Global Type 1 diabetes market is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in ...

Nature gives the first evidence Novo Nordisk's Fiasp (rapid-acting insulin aspart) has been approved by the US FDA for use in insulin pumps! Biotech company SpringWorks Therapeutics plans to raise ...

Sikkim Casino entry fee Fountain Medical Completes $62 Million Series D Financing Novo Nordisk's Fiasp (rapid-acting insulin aspart) has been ap ...

Mahadev Online betting login Another new drug from Ionis, the leader in antisense oligonucleotides, has been approved for marketing in the ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Novo Nordisk ( (NVO)) just unveiled an announcement. Novo Nordisk has announced the successful results of its ...

The picture shows an ampule of quick-acting ... high insulin prices is unconstitutional. In addition to UHC, the lawsuits filed in New Jersey name drug manufacturers Eli Lilly, Novo Nordisk ...

This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...